Text this: Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective

導出完成 —  

 _    _    _    _    _____     __   __    _  __  
| || | || | || | || |  __ \\   \ \\/ //  | |/ // 
| || | || | || | || | |  \ ||   \ ` //   | ' //  
| \\_/ || | \\_/ || | |__/ ||    | ||    | . \\  
 \____//   \____//  |_____//     |_||    |_|\_\\ 
  `---`     `---`    -----`      `-`'    `-` --`